BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Myasthenia gravis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for myasthenia gravis: 74 (38 sponsors; 7 newly posted in the last 180 days, 1 stopped in the last 180 days; 4 new-entrant sponsors). Momentum score 22.3, rank 21 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 8, Phase 2 17, Phase 3 29, Phase 4 3, N/A 16.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| argenx ARGX | 12 | P3 5, NA 4, P4 1, P2 2 | 1 | 1 |
| UCB Biopharma SRL | 6 | P3 5, P4 1 | 0 | 1 |
| Alexion Pharmaceuticals, Inc. | 8 | P3 4, NA 3, P4 1 | 0 | 1 |
| Janssen Research & Development, LLC | 3 | P3 3 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 3 | P3 2, P2 1 | 0 | 1 |
| Cartesian Therapeutics RNAC | 3 | P2 2, P3 1 | 0 | 1 |
| Amgen AMGN | 2 | P2 1, P3 1 | 0 | 0 |
| Dianthus Therapeutics DNTH | 2 | P3 1, P2 1 | 1 | 0 |
| Immunovant Sciences GmbH IMVT | 1 | P3 1 | 0 | 0 |
| Kyverna Therapeutics KYTX | 1 | P3 1 | 0 | 0 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 | P3 1 | 0 | 0 |
| Regeneron Pharmaceuticals REGN | 1 | P3 1 | 0 | 0 |
| RemeGen Co., Ltd. | 1 | P3 1 | 0 | 1 |
| Shanghai Jiaolian Drug Research and Development Co., Ltd | 1 | P3 1 | 0 | 1 |
| Vor Biopharma VOR | 1 | P3 1 | 0 | 1 |
| AstraZeneca AZN | 3 | NA 3 | 0 | 0 |
| BioSensics | 2 | NA 2 | 0 | 0 |
| Kite, A Gilead Company | 2 | P1 2 | 0 | 0 |
| TG Therapeutics, Inc. TGTX | 2 | P2 1, P1 1 | 1 | 1 |
| Aurinia Pharmaceuticals Inc. AUPH | 1 | P2 1 | 0 | 0 |
| Biogen BIIB new entrant | 1 | P2 1 | 1 | 0 |
| Cabaletta Bio CABA | 1 | P2 1 | 0 | 0 |
| Candid Therapeutics | 1 | P1 1 | 0 | 0 |
| Changchun GeneScience Pharmaceutical Co., Ltd. new entrant | 1 | P2 1 | 1 | 0 |
| COUR Pharmaceutical Development Company, Inc. | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Biogen, Changchun GeneScience Pharmaceutical Co., Ltd..
Recently stopped trials
- NCT05403541 Immunovant Sciences GmbH - terminated: Sponsor Decision Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | NMD Pharma A/S | NCT06414954 Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Myasthenia Gravis; Myasthenia Gravis, MuSK | recruiting | 84 |
| 2026-12-15 est. | P3 | Alexion Pharmaceuticals, Inc. | NCT06607627 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | Generalized Myasthenia Gravis; gMG | recruiting | 12 |
| 2026-12-30 est. | P2/P3 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06447597 A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | Generalized Myasthenia Gravis | recruiting | 104 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | Myasthenia Gravis, Ocular | recruiting | 120 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-05 | P2/P3 | UCB Biopharma SRL | NCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 14 |
| 2026-07-31 | P3 | UCB Biopharma SRL | NCT04225871 Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 200 |
| 2026-07-15 est. | P3 | Alexion Pharmaceuticals, Inc. | NCT05644561 Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis; gMG | active not recruiting | 12 |
| 2026-06 est. | P1/P2 | COUR Pharmaceutical Development Company, Inc. | NCT06106672 Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Myasthenia Gravis; Generalized Myasthenia; AChR Myasthenia Gravis; MuSK MG | active not recruiting | 54 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "myasthenia gravis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.